Genenta Science (Nasdaq: GNTA) Alternatives & Competitors
12 companies similar to Genenta Science (Nasdaq: GNTA) — Genenta is a clinical stage immuno-oncology company
Companies similar to Genenta Science (Nasdaq: GNTA)
Minerva Biotechnologies
We see the future first
Kiromic Biopharma, Inc.
Cell therapy company with end-to-end bioinformatic, AI targeting, and manufacturing techno...
Carisma Therapeutics
Pioneering CAR Macrophage Immunotherapy to Target Solid Tumors
Alpheus Medical, Inc
Changing the way cancer is treated.
Rival Readout
Competing with Genenta Science (Nasdaq: GNTA)? We do this properly.
10 rivals, 90 days of dated moves, ranked by what matters and sourced, in 7 business days.
Nkarta, Inc.
A New Way Forward for Autoimmune Disease
Vor Bio
Vor Bio's vision is to cure blood cancers through cell and genome engineering.
Altheia Science
Altheia Science develops treatments for autoimmune diseases and cancer using innovative to...
Enterome
Delivering the promise of immunotherapy
Trillium Therapeutics Inc.
Clinical stage immuno-oncology company developing innovative therapies for the treatment o...
ImmunoCellular Therapeutics Ltd
Pioneering immune-based therapies to harness the body's defenses against cancer through ad...
MetiMedi Co., Ltd.
MetiMedi is developing a first-in-class oral immunotherapeutic small molecule in Phase 2 f...
Celularity Inc.
A next-gen Biotech company creating off-the-shelf cellular medicines for Cancer, Infectiou...
About Genenta Science (Nasdaq: GNTA)
Genenta Science is a biotechnology startup based in Italy, founded in 2014, with a focus on developing a proprietary hematopoietic stem cell therapy for solid tumor cancers. Their flagship product, Temferon™, involves ex-vivo gene transfer into autologous Tie2+ hematopoietic stem/progenitor cells to deliver immunomodul...
Hematopoietic Stem Cell Therapy, Solid Tumor Cancers, Gene Therapy, Immunotherapy, Cell Therapy, Clinical-Stage Biotech, Glioblastoma Multiforme, Cancer Treatment, Immuno-Oncology, Tie2+ Hematopoietic Stem Cells, Phase 1/2a Clinical Trial, MGMT Gene Promoter, Temferon, Ex-Vivo Gene Transfer
Frequently Asked Questions
From the desk
Mapping a market? Start with a Rival Readout.
In 7 business days we read 10 rivals around Genenta Science (Nasdaq: GNTA): 90 days of dated moves, ranked by what matters to you, each with its source. Fully credited if you continue.
Compiled from the BounceWatch company index. We last looked at Genenta Science (Nasdaq: GNTA) on 12 Sep 2024. The 12 companies listed here were last checked between 11 Sep 2024 and 22 Jun 2026. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.